Trial Profile
Apatinib mesylate tablets for the maintain treatment of platinum-sensitive recurrent ovarian cancer after first-line chemotherapy: a prospective, one-arm clinical study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 27 Feb 2018 New trial record